Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Monopar TherapeuticsMNPR · Entity 5152 | Chief Operating Officer | September 30, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Monopar Therapeutics
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,054 |
Ending reported balance
After 2026-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-30 · Exercise / conversion · Acquired 4,384 · Balance 59,998 F1: Represents shares acquired on vesting and settlement of restricted stock units. Row 2 · 2026-09-30 · Tax withholding · Disposed 1,944 · Balance 58,054 F2: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 35,115 |
Reported balance
After 2026-09-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-30 · Exercise / conversion · Disposed 4,384 · Balance 35,115 F1: Represents shares acquired on vesting and settlement of restricted stock units. F3: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4: On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5: On December 2, 2025, the reporting person was granted 13,919 restricted stock units, vesting 6/48ths (1,740) on June 30, 2026, and 3/48ths (870 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares acquired on vesting and settlement of restricted stock units.
F2: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
F3: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F4: On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F5: On December 2, 2025, the reporting person was granted 13,919 restricted stock units, vesting 6/48ths (1,740) on June 30, 2026, and 3/48ths (870 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2023 Filed Jan 4, 2024 00:39 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 8,952 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-000486 · rdgdoc.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 23:30 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 8,953 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-027581 · rdgdoc.xml · derivative · entry 3 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,127 Underlying: Common Stock · 8,953 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 23:30 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 2,624 | $0.62 | $1,626.62 |
DisclosureSEC source: 0001437749-23-027581 · rdgdoc.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,916 F3 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 23:30 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 8,953 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-027581 · rdgdoc.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 22:51 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 13,841 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-019263 · rdgdoc.xml · derivative · entry 3 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,080 Underlying: Common Stock · 13,841 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,889 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,889 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 22:51 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 4,057 | $0.86 | $3,468.74 |
DisclosureSEC source: 0001437749-23-019263 · rdgdoc.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,587 F3 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 22:51 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 13,841 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-019263 · rdgdoc.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:15 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 4,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-009330 · rdgdoc.xml · derivative · entry 3 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,687 Underlying: Common Stock · 4,063 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:15 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 1,154 | $1.39 | $1,604.06 |
DisclosureSEC source: 0001437749-23-009330 · rdgdoc.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,803 F3 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:15 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 4,063 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-009330 · rdgdoc.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 23:44 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 78,234 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-002515 · rdgdoc.xml · derivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,984 Underlying: Common Stock · 78,234 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 6/48ths on June 30, 2023 and 3/48ths per quarter thereafter (September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025, March 31, 2026, June 30, 2026, September 30, 2026, December 31, 2026) F2 · derivative.expiration_date: RSUs vest 6/48ths on June 30, 2023 and 3/48ths per quarter thereafter (September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025, March 31, 2026, June 30, 2026, September 30, 2026, December 31, 2026) Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 23:44 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 102,688 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001437749-23-002515 · rdgdoc.xml · derivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,688 Underlying: Common Stock · 102,688 shares Expires 2033-02-01 F1 · derivative.exercise_date: Options vest 6/48ths on June 30, 2023 and 1/48th per month thereafter. Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 21:07 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 4,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-000169 · rdgdoc.xml · derivative · entry 3 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Stock · 4,062 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 21:07 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 1,406 | $2.37 | $3,332.22 |
DisclosureSEC source: 0001437749-23-000169 · rdgdoc.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,894 Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 21:07 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 4,062 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-000169 · rdgdoc.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:58 UTC | Monopar Therapeutics MNPR · Entity 5152 | PurchaseCommon Stock | 10,000 | $3.15 | $31,500.00 |
DisclosureSEC source: 0001863624-22-000001 · primary_doc.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,238 Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 21:58 UTC | Monopar Therapeutics MNPR · Entity 5152 | PurchaseCommon Stock | 6,053 | $3.00 | $18,159.00 |
DisclosureSEC source: 0001863624-22-000001 · primary_doc.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,238 Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 23:42 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 4,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-013278 · section16.xml · derivative · entry 3 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,812 Underlying: Common Stock · 4,063 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 23:42 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 1,191 | $1.52 | $1,810.32 |
DisclosureSEC source: 0001654954-22-013278 · section16.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,185 Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 23:42 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 4,063 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-013278 · section16.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:17 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 8,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-009149 · section16.xml · derivative · entry 3 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,875 Underlying: Common Stock · 8,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:17 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 2,812 | $2.30 | $6,464.79 |
DisclosureSEC source: 0001654954-22-009149 · section16.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,313 Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:17 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 8,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-009149 · section16.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| February 02, 2022 Filed Feb 5, 2022 00:29 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 65,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-001167 · section16.xml · derivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 6/48ths on June 30, 2022 and 3/48ths per quarter thereafter (September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025) F2 · derivative.expiration_date: RSUs vest 6/48ths on June 30, 2022 and 3/48ths per quarter thereafter (September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025) Read SEC document |
| February 02, 2022 Filed Feb 5, 2022 00:29 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 85,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001654954-22-001167 · section16.xml · derivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: Options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:07 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 30,000 | $0.00 Strike: $5.89 | $0.00 |
DisclosureSEC source: 0001654954-21-007591 · section16.xml · derivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-05-31 F1 · derivative.exercise_date: Options vest 6/48ths on November 30, 2021 and 1/48th monthly on the last day of each month thereafter. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:11 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 70,000 | $0.00 Strike: $5.76 | $0.00 |
DisclosureSEC source: 0001654954-21-006531 · section16.xml · derivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-05-31 F1 · derivative.exercise_date: Options vest 6/48ths on November 30, 2021 and 1/48th monthly on the last day of each month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.